

Original article

Tricuspid but not Mitral Regurgitation Determines Mortality After TAVI in Patients With Nonsevere Mitral Regurgitation



Ignacio J. Amat-Santos,^{a,*} Javier Castrodeza,^a Luis Nombela-Franco,^b Antonio J. Muñoz-García,^c Enrique Gutiérrez-Ibanes,^d José M. de la Torre Hernández,^e Juan G. Córdoba-Soriano,^f Pilar Jiménez-Quevedo,^b José M. Hernández-García,^c Ana González-Mansilla,^d Javier Ruano,^e Javier Tobar,^a María Del Trigo,^b Silvio Vera,^a Rishi Puri,^g Carolina Hernández-Luis,^a Manuel Carrasco-Moraleja,^a Itziar Gómez,^a Josep Rodés-Cabau,^g and José A. San Román^a

^aDepartamento de Cardiología, CIBERCV, Hospital Clínico Universitario, Valladolid, Spain

^bDepartamento de Cardiología, Hospital Clínico Universitario San Carlos, Madrid, Spain

^cDepartamento de Cardiología, Hospital Clínico Virgen de la Victoria, Málaga, Spain

^dDepartamento de Cardiología, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

^eDepartamento de Cardiología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

^fDepartamento de Cardiología, Hospital General Universitario, Albacete, Spain

^gDepartment of Cardiology, Quebec Heart and Lung Institute, Quebec, Canada

Article history:

Received 20 April 2017

Accepted 2 August 2017

Available online 27 October 2017

Keywords:

Mitral regurgitation

Tricuspid regurgitation

Transcatheter aortic valve implantation

Multivalvular disease

ABSTRACT

Introduction and objectives: Many patients undergoing transcatheter aortic valve implantation (TAVI) have concomitant mitral regurgitation (MR) of moderate grade or less. The impact of coexistent tricuspid regurgitation (TR) remains to be determined. We sought to analyze the impact of moderate vs none-to-mild MR and its trend after TAVI, as well as the impact of concomitant TR and its interaction with MR.

Methods: Multicenter retrospective study of 813 TAVI patients treated through the transfemoral approach with MR ≤ 2 between 2007 and 2015.

Results: The mean age was 81 ± 7 years and the mean Society of Thoracic Surgeons score was 6.9 ± 5.1 . Moderate MR was present in 37.3% of the patients, with similar in-hospital outcomes and 6-month follow-up mortality to those with MR < 2 (11.9% vs 9.4%; $P = .257$). However, they experienced more rehospitalizations and worse New York Heart Association class ($P = .008$ and $.001$, respectively). Few patients (3.8%) showed an increase in the MR grade to > 2 post-TAVI. The presence of concomitant moderate/severe TR was associated with in-hospital and follow-up mortality rates of 13% and 34.1%, respectively, regardless of MR grade. Moderate-severe TR was independently associated with mortality (HR, 18.4; 95%CI, 10.2–33.3; $P < .001$).

Conclusions: The presence of moderate MR seemed not to impact short- and mid-term mortality post-TAVI, but was associated with more rehospitalizations. The presence of moderate or severe TR was associated with higher mortality. This suggests that a thorough evaluation of the mechanisms underlying concomitant mitral and tricuspid valve regurgitation should be performed to determine the best strategy for avoiding TAVI-related futility.

© 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

La insuficiencia tricúspide, y no la insuficiencia mitral, determina la mortalidad en pacientes que presentan insuficiencia mitral no grave previa a TAVI

RESUMEN

Introducción y objetivos: Muchos pacientes sometidos a implante percutáneo de válvula aórtica (TAVI) presentan insuficiencia mitral (IM) de grado moderado o menor. El impacto de la insuficiencia tricuspídea (IT) sigue sin resolverse. Se analiza el impacto de la IM moderada frente a leve-ausente y su evolución, y de la IT concomitante y su interacción con la IM.

Métodos: Estudio retrospectivo multicéntrico de 813 pacientes tratados con TAVI entre 2007 y 2015 con IM ≤ 2 y abordaje transfemoral.

Resultados: La edad media fue 81 ± 7 años y el *Society of Thoracic Surgeons-score* fue de $6,9 \pm 5,1$. El 37,3% presentó IM moderada, con resultados comparables intrahospitalarios y de mortalidad a 6 meses frente a IM < 2 (11,9 frente a 9,4%; $p = 0,257$). Sin embargo, experimentaron más rehospitalizaciones y peor clase de la *New York Heart Association* ($p = 0,008$ y $0,001$, respectivamente). Solo un 3,8% demostró un aumento en el grado de IM > 2 tras el TAVI. La presencia de IT moderada/grave se asoció con una mortalidad

Palabras clave:

Insuficiencia mitral

Insuficiencia tricuspídea

Implante percutáneo de válvula aórtica

Enfermedad multivalvular

* Corresponding author: Departamento de Cardiología, Hospital Clínico Universitario, Ramón y Cajal 3, 47005 Valladolid, Spain.
E-mail address: ijamat@gmail.com (I.J. Amat-Santos).

intrahospitalaria y de seguimiento del 13 y el 34,1%, independientemente del grado de IM. La IT moderada-grave fue predictor independiente de mortalidad (HR = 18,4; IC95%, 10,2-33,3; $p < 0,001$).

Conclusiones: La presencia de IM moderada no supuso mayor mortalidad a corto-medio plazo tras el TAVI, pero asoció más rehospitalizaciones. La presencia de IT moderada/grave implicó mayor mortalidad. Esto sugiere que una evaluación minuciosa de los mecanismos subyacentes entre ambas insuficiencias valvulares debe realizarse para determinar la mejor estrategia para evitar la futilidad relacionada con TAVI.

© 2018 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Abbreviations

MR: mitral regurgitation
PHT: pulmonary hypertension
TAVI: transcatheter aortic valve implantation
TR: tricuspid regurgitation

INTRODUCTION

Aortic stenosis is the most frequently treated heart valve disease in our society, followed by mitral regurgitation (MR).¹ Double valve replacement may cause up to a 5-fold increase in risk for cardiac surgery compared with single valve replacement, which has limited the surgical management of dual-valve disease to less than 30% of the patients with these conditions.² This is despite the recommendation for double valve intervention by clinical practice guidelines if both valves are severely diseased.^{3,4} Transcatheter aortic valve implantation has emerged as an alternative treatment strategy for patients with multivalvular disease, but the impact of significant concomitant MR has received limited evaluation in the main TAVI trials.^{5,6} Several studies, however, have suggested heightened mortality when significant MR persists following TAVI.⁷⁻¹⁰

In many patients undergoing TAVI, concomitant MR—when present—is usually of mild-to-moderate severity. There is a paucity of data on the implications of coexistent MR of varying severity in the post-TAVI population, which may be present in up to 70% of these patients. Additionally, although some studies have assessed the impact of tricuspid regurgitation (TR) and pulmonary hypertension (PHT) post-TAVI,¹¹⁻¹⁵ the role played by right-heart hemodynamics in the outcomes of concomitant nonsignificant mitral disease is currently unknown. A better understanding of the interplay between dual-valve (and dual-sided) disease could shed further light on TAVI-related outcomes, including TAVI-related futility, which ultimately could impact decision-making strategies for such patients, while also raising further speculation on alternative percutaneous treatment strategies. The aim of this study was: *a*) to analyze the clinical impact of moderate vs none-to-mild MR and its variations following TAVI; and *b*) to determine the impact of concomitant TR in TAVI recipients with no, mild, or moderate MR.

METHODS

Study Population

Between August 2007 and January 2015, 1110 consecutive patients underwent TAVI in 6 different centers. The effect of moderate (3+) and severe (4+) MR has previously been reported in this study cohort.⁸ In the present analysis, we included 813 patients without prior mitral prostheses, with moderate (grade 2) MR severity or less with severe aortic stenosis. Only patients treated via the transfemoral approach were included. All patients were

previously accepted for TAVI by a multidisciplinary team and subsequently each patient was evaluated to determine the most appropriate valve type/size and approach. Finally, clinical outcomes according to Valve Academic Research Consortium 2 (VARC-2) criteria were evaluated at each clinical visit.¹⁶

Imaging Evaluation

All patients underwent complete 2-dimensional and color-Doppler echocardiography at baseline, before discharge, and at 1- and 6-months post-TAVI. All images were digitally stored. Off-line retrospective analysis of the grade and etiology of MR and TR was performed by an experienced echocardiographer blinded to further data of the post-TAVI outcomes. Other parameters included left ventricular indices (end-diastolic and end-systolic diameters, left ventricular ejection fraction obtained by biplane Simpson's method), determination of the organic or functional/ischemic origin of the MR, mitral and aortic annular diameters, tenting height and area when indicated, and pulmonary artery systolic pressure. Baseline measurements were graded following the recommendations of the European Association of Echocardiography.¹⁷

Tricuspid regurgitation and MR grade were assessed following the European and American Guidelines on Echocardiography^{3,4} and accordingly classified as follows: 0 (none), 1+ (mild), 2+ (nonsignificant moderate), 3+ (significant moderate), and 4+ (severe). Patients were classified into 2 groups according to the grade of baseline MR following the same guidelines^{3,4}: *a*) none or mild (0 and 1+), and *b*) nonsignificant moderate MR (2+). Patients with significant moderate (3+) or severe MR (4+) were excluded from this study. For statistical purposes, any decrease of 1 or more grades was considered an improvement of the MR. Pulmonary artery systolic pressure was estimated by echocardiography as previously described elsewhere³ and the remaining echocardiographic parameters, including assessment of the function of other valves and the left ventricle, followed the recommendations of scientific societies.^{3,4}

Statistical Analysis

Data are expressed as absolute frequency and percentage for qualitative variables. Quantitative variables are described as mean \pm standard deviation or median (25th-75th interquartile range) depending on their distribution. Group comparisons according to the grade and improvement of MR were analyzed using the Student *t* test or its nonparametric equivalent, the Mann-Whitney *U* test for continuous variables, and the chi-square test or Fisher exact test for categorical variables. Statistical significance was defined as a *P* value $< .05$. Multivariate analysis was performed to determine independent predictors of 6-month overall mortality. Survival curves for 6-month overall and cardiac mortality were compared using a log rank test according to the MR grade and as affected by the TR for each grade.

All analyses were conducted using the statistical package IBM SPSS Statistics, version 20.0.

RESULTS

From a total of 1110 unselected TAVI patients whose main characteristics have already been reported,⁸ 813 (73.2%) with MR $\leq 2+$ and who were treated via a transfemoral approach were selected for inclusion in the current analysis.

Clinical and Imaging Baseline Characteristics of the Study Population

The mean age of the study sample was 81 ± 7 years with 35.8% being men. The mean logistic EuroSCORE and the Society of Thoracic Surgeons scores were $15.9 \pm 10.5\%$ and 6.9 ± 5.1 , respectively. The main clinical and imaging baseline characteristics of the whole sample and according to MR grade are summarized in Table 1.

A total of 303 patients (37.3%) had moderate MR and 510 patients (62.7%) had no or mild MR. There were several differences in the baseline characteristics between the groups including older age and lower left ventricular ejection fraction in patients with moderate MR. Those with worse MR grade also had higher rates of atrial fibrillation (31.3% vs 24.2%; $P = .034$) and New York Heart Association (NYHA) class III-IV (78.2% vs 67.2%; $P = .003$). Median aortic peak gradient was lower in the none-to-mild MR group (75 [63–89] mmHg vs 78 [65–96] mmHg; $P = .038$)

but without differences in the median aortic valve area. Concerning the mitral apparatus, the presence of degenerative changes was detected in 57.4% of patients with moderate MR vs 77.3% in those with none-to-mild MR ($P = .001$).

Periprocedural and Follow-up Outcomes of the Study Population

The main procedural, in-hospital, and follow-up outcomes are reported in Table 2. Changes in MR grade from baseline up to 6 months of follow-up are shown in Figure 1 and the predictors of this improvement are depicted in Table 1 of the supplementary material. Twenty-seven percent of patients had no MR at baseline and this percentage increased up to 40% postprocedurally. Of patients with moderate MR at baseline, 3.8% experienced a deterioration in their MR grade, 15.6% improved, and the rest experienced no change.

Aortic valvuloplasty was performed in most patients (76.8% in those with baseline MR $< 2+$ vs 80.9% in those with MR = 2+; $P = .177$), and the predominant type of implanted valve was the self-expandable CoreValve system (75.8% of the entire cohort) including the 2 more recent device iterations: CoreValve ReValving System and CoreValve Evolute-R (CoreValve, Medtronic, United States). Although self-expanding devices were the preferred

Table 1

Baseline and Echocardiographic Characteristics According to the Grade of Mitral Regurgitation (Moderate vs Mild or None)

	None-to-mild MR (MR < 2) n = 510	Moderate MR (MR = 2) n = 303	P
Baseline characteristics			
Age, y	79.9 \pm 6.7	82.1 \pm 6.9	.001
Sex, male	176/510 (34.5)	115/303 (38)	0.322
BMI, kg/m ²	28.5 [25.3–32.3]	27.2 [24.4–30.6]	.001
STS score, %	6.9 \pm 5.1	6.9 \pm 4.9	.999
Diabetes mellitus	207/505 (41)	99/296 (33.5)	.034
Hypertension	425/506 (84)	235/296 (79.4)	.100
Dyslipidemia	251/445 (56.4)	61/120 (50.8)	.276
Coronary artery disease	213/504 (42.3)	114/292 (39)	.373
Previous PCI	140/506 (27.7)	54/296 (18.2)	.003
Previous CABG	60/504 (11.9)	36/296 (12.2)	.914
Chronic kidney disease	115/445 (25.8)	23/120 (19.2)	.131
Previous atrial fibrillation	115/476 (24.2)	86/275 (31.3)	.034
NYHA III-IV	244/363 (67.2)	187/239 (78.2)	.003
Echocardiographic findings			
Aortic peak gradient, mmHg	75 [63–89]	78 [65–96]	.038
Aortic mean gradient, mmHg	46 [39–57]	46 [38–57]	.822
LVEF, %	64 [52–71]	60 [50–61]	< .001
Aortic regurgitation III-IV	58/446 (13)	13/182 (7.1)	.023
Aortic valve area, cm ²	0.62 [0.5–0.76]	0.67 [0.5–0.8]	.097
Aortic annulus, mm	21.9 [20–23]	22 [20–24]	.139
Etiology of MR			
Degenerative	360/466 (77.3)	151/263 (57.4)	.001
Functional	106/466 (22.7)	112/263 (42.6)	
Tricuspid regurgitation ≥ 2	80/510 (15.7)	128/300 (42.7)	< .001
Severe PHT (PASP > 55 mmHg)	124/315 (39.4)	95/172 (55.2)	.001
Mitral annulus diameter, mm	45 [33–60]	50 [40–62.5]	< .001
Tenting height, mm	5.6 \pm 1.8	10.2 \pm 3.9	.001
Tenting area, mm ²	30.7 \pm 48.9	140 \pm 132.6	.001

BMI, body mass index; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PHT, pulmonary hypertension; PASP, pulmonary artery systolic pressure; STS, Society of Thoracic Surgeons. Data are expressed as mean \pm standard deviation, No. (%), or median [interquartile range].

Table 2
Periprocedural and Follow-up Outcomes According to the Grade of Baseline Mitral Regurgitation

	None-to-mild MR (MR < 2) n = 510	Moderate MR (MR = 2) n = 303	P
Procedural outcomes			
Transfemoral approach	510/510 (100)	303/303 (100)	
Balloon valvuloplasty	360/469 (76.8)	245/303 (80.9)	.177
Type of valve			
Balloon-expandable	80/506 (15.8)	114/297 (38.4)	.001
Self-expandable	426/506 (84.2)	183/297 (61.6)	
Number of prostheses			
1	501/506 (99)	285/297 (96)	.004
2	5/506 (1)	12/297 (4)	
Successful device implantation	480/499 (96.2)	282/297 (94.9)	.402
Need for hemodynamic support	6/510 (1.2)	1/303 (0.3)	.267
Valve embolization	1/510 (0.2)	7/303 (2.3)	.005
In-hospital outcomes			
Cerebrovascular event	17/440 (3.9)	1/120 (1)	.141
Permanent pacemaker	104/448 (23.2)	69/263 (26.2)	.365
New onset atrial fibrillation	28/317 (8.8)	20/213 (9.4)	.827
New persistent LBBB	141/320 (44.1)	102/218 (46.8)	.533
Aortic regurgitation III-IV	8/481 (1.7)	6/250 (2.4)	.374
Length of stay, d	5.6 ± 3.5	10.1 ± 8.9	.001
In-hospital mortality	25/510 (4.9)	13/303 (4.3)	.690
1-month follow-up outcomes			
NYHA III-IV	3/382 (1)	9/92 (9.8)	.001
Hospitalization	15/384 (3.9)	11/106 (10.4)	.009
Mortality	32/510 (6.3)	20/302 (6.6)	.908
6-month follow-up outcomes			
NYHA III-IV	9/350 (2.6)	9/83 (10.8)	.001
Hospitalization	17/364 (4.7)	11/91 (12.1)	.008
Mortality	48/510 (9.4)	36/302 (11.9)	.257
Cardiovascular mortality	25/45 (56)	18/36 (50)	.248

LBBB: left bundle branch block; MR, mitral regurgitation; NYHA, New York Heart Association. Data are expressed as mean ± standard deviation or No. (%).




Figure 1. Changes in MR grade from baseline up to 6 months of follow-up as assessed by transthoracic echocardiography. FU, follow-up; MR, mitral regurgitation.

devices across both groups, those with moderate MR at baseline were more likely to receive a balloon-expandable prosthesis (38.4% vs 15.8%; $P = .001$), (Edwards, Edwards Lifesciences, United States) with no differences in the rate of successful device implantation according to VARC-2 criteria.¹⁶

Concerning in-hospital outcomes, no differences were found in the rate of stroke, permanent pacemaker implantation, new-onset

atrial fibrillation (8.8% for MR < 2+ vs 9.4% for MR = 2+; $P = .827$), or significant aortic regurgitation (1.7% vs 2.4%; $P = .374$). Patients with moderate MR had a longer length of stay (7 [5–12] days vs 5 [4–6] days in patients with baseline MR < 2+; $P = .001$). In-hospital death was similar between the 2 groups (4.9% vs 4.3%; $P = .69$).

At 1-month follow-up, compared with patients with a baseline MR of 2+, those with MR < 2+ had better functional capacity (99% were NYHA I-II vs 90.2%; $P = .001$) and overall mortality was also comparable (6.3% vs 6.6%; $P = .85$). However, the need for new hospitalizations was higher in patients with baseline MR = 2+ (10.4%) than in those with lower MR grades (3.9%, $P = .009$). Similar tendencies persisted at 6-months' follow-up, with no differences in overall and cardiac mortality between the 2 patient groups and greater rehospitalization rate in the moderate MR group. Survival curves according to the grade of MR are represented in Figure 2.

Influence of Tricuspid Regurgitation on Global Outcomes

The main baseline, procedural, and in-hospital characteristics according to baseline TR grade were comparable, as summarized in Table 2 of the supplementary material. The distribution of TR grade according to the baseline MR grade (moderate vs none-to-mild) is shown in Figure 3. At baseline, 15.7% of the patients with MR < 2+ had at least moderate TR (2+), whereas this rate was 42.7% in the moderate MR group ($P = .001$). As summarized in the Figure of the




Figure 2. Survival curves according to the baseline MR grade. MR, mitral regurgitation.




Figure 3. Distribution of TR grade according to the baseline MR grade (moderate vs mild-none). MR, mitral regurgitation; TR, tricuspid regurgitation. *Not available in 3 patients (1%).

supplementary material, those with a higher baseline TR grade had more progressive mitral valve disease ($P < .001$) at the 6-month follow-up. In addition, the rate of severe PHT was also higher in the moderate MR group (55.2%) compared with 39.4% in the none-to-mild MR group ($P = .001$). At 6 months of follow-up, the rate of PHT was comparable among both groups.

As depicted in Figure 4, the probability of survival was influenced by the presence of TR (TR $\geq 2+$). Indeed, the rate of 6-month mortality among patients with moderate MR was 11.9% with no differences compared with patients with none-to-mild MR at baseline (9.4%; $P = .257$) and this absence of differences remained if TR was $< 2+$ ($P = .092$), with a 6-month mortality rate of 2.17%. On the contrary, the presence of TR $\geq 2+$ increased overall mortality ($P < .001$) irrespective of the MR grade, with a rate of in-hospital mortality of 13% and 6-month mortality of 34.1%. The combination of baseline moderate MR and TR $\geq 2+$ was associated with an overall mortality rate of 27.4% whereas none-to-mild MR combined with none-to-mild TR was associated with a 6-month mortality rate of 2.8% ($P < .001$).

Predictors of 6-month Mortality

The main factors associated with 6-month mortality are summarized in Table 3. Independent predictors of mortality identified on multivariate analysis, with a C-index of 0.817 (95% confidence interval, 0.770–0.864), were the presence of significant baseline TR, the development of cerebrovascular events after TAVI, and valve embolization during the procedure.

DISCUSSION

Nonsignificant baseline MR is far more common in TAVI candidates than significant MR, as recently pointed out by Mavromatis.¹⁸ In itself, within the nonsevere MR spectrum, it has no specific or direct influence on post-TAVI outcomes according to our results. This contrasts with poorer outcomes reported for patients with moderate (3+) and severe (4+) MR.⁸ However, coexisting baseline TR of moderate or severe grades seems to significantly impact post-TAVI outcomes in the presence of baseline MR ≤ 2 with a 10-fold increase in follow-up mortality. These findings highlight that the presence of severe aortic stenosis together with moderate regurgitation of both atrioventricular valves (even 2+) should be meticulously evaluated pre-TAVI to clarify their mechanism and the potential outcomes with the various current therapeutic strategies.

Changes in Moderate Mitral Regurgitation and Impact on Outcomes

As previously reported,⁸ 16% of the patients in the overall cohort ($n = 1110$) had significant MR, which was independently associated with poorer outcomes in line with former studies.^{7,9–12} Only 3.8% of the patients with baseline MR of 2+ severity progressed to significant MR, but this may be an underestimate given the relatively short follow-up period. Furthermore, no relationship could be found the etiology (functional vs degenerative) of MR and the mortality, which could also be explained by the inaccuracy of this simple classification in a group of patients with several concomitant degenerative cardiac changes.¹⁰ In addition, up to 12% of the patients with baseline MR of 2+ improved to none or mild MR 6 months after TAVI, with an associated decrease in pulmonary artery systolic pressure and an improvement in NYHA class in all patients.

Although some discrepancies exist regarding the impact on outcomes of atrioventricular valve regurgitation post-TAVI in aortic stenosis patients, most of them show an improvement in the grade of the regurgitation with a parallel improvement in heart failure symptoms or functional capacity.¹⁴ However, as pointed out by Barbanti et al.,¹⁹ the response of TR to TAVI was extremely variable, and in general, TR was not an independent predictor of mortality. This highlights the relevance of our results showing a significant impact of TR on post-TAVI mortality in a selected group of patients with MR grade ≤ 2 .¹⁵

Prognostic Impact of Tricuspid Regurgitation and Pulmonary Hypertension in Patients With Nonsignificant Mitral Regurgitation

In the group of patients with persistent nonsignificant MR but who had a significant grade of TR, 6-month survival was significantly lower (Figure 4). Of note, no clinically relevant baseline differences were found according to baseline TR grade, including a comparable rate of PHT and right ventricular function, reinforcing the idea that moderate and severe TR is a marker of




Figure 4. Survival curves according to the baseline MR and TR grade. MR, mitral regurgitation; TR, tricuspid regurgitation.

Table 3

Main Predictors of 6-month Mortality in the Overall Transcatheter Aortic Valve Implantation Population

Variables	Univariate analysis		Univariate analysis		Multivariate analysis	
	Death at 6 months FU N = 84	Alive at 6 months FU N = 728	HR (95%CI)	P	HR (95%CI)	P
Dyslipidemia	47/71 (66.2)	265/494 (53.6)	1.64 (1.00-2.68)	.049	—	—
Previous atrial fibrillation	15/80 (18.8)	186/670 (27.8)	0.62 (0.35-1.08)	.092	—	—
Etiology of MR (degenerative)	46/77 (59.7)	464/651 (71.3)	0.623 (0.40-0.98)	.042	—	—
Balloon valvuloplasty	69/79 (87.3)	535/692 (77.3)	1.95 (1.01-3.79)	.048	—	—
Type of valve, SE	69/82 (84.1)	540/720 (75)	1.69 (0.94-3.06)	.082	—	—
Need for hemodynamic support	4/84 (4.8)	3/728 (0.4)	11.75 (4.30-32.14)	< .001	—	—
Valve embolization	4/84 (4.8)	4/728 (0.5)	7.00 (2.56-19.13)	< .001	4.30 (1.57-11.83)	.005
Successful device implantation	74/82 (90.2)	687/713 (96.4)	0.325 (0.17-0.67)	.003	—	—
Sepsis	9/84 (10.7)	19/726 (2.6)	3.79 (1.90-7.56)	< .001	—	—
Cerebrovascular event	5/84 (6)	13/728 (1.8)	3.04 (1.23-7.50)	.016	3.14 (1.27-7.77)	.014
Baseline TR ≥ 2	71/84 (84.5)	137/726 (18.9)	18.73 (10.36-33.85)	< .001	18.43 (10.19-33.34)	< .001
Baseline MR = 2	36/84 (42.9)	266/728 (36.5)	1.26 (0.82-1.95)	.289	—	—
Hospitalization at 1 month	5/48 (10.4)	21/442(4.8)	2.22 (0.88-5.60)	.092	—	—

95%CI, 95% confidence interval; FU, follow-up; HR, hazard ratio; MR, mitral regurgitation; SE, self-expandable; TR, tricuspid regurgitation. Unless otherwise indicated, data are expressed as No. (%).

poor prognosis in itself. Recent data suggest that both TR and PHT influence long-term survival post-TAVI.^{11–15} However, the impact of these 2 parameters obviously varies. By selecting a subgroup of patients with a lower grade of MR, we aimed to clear the way for interpreting the impact of TR and PHT. Indeed, our findings suggest that the presence of significant TR in the absence of significant MR in patients with severe aortic stenosis has a strong prognostic impact and requires further investigation. In some cases, treating the etiology of a tricuspid annular dilation (such as PHT resulting from different baseline conditions) may be enough. However, in some other cases, the presence of large tricuspid annuli (> 40 mm of diameter)²⁰ may tip the balance in favor of surgical (or percutaneous in the near future) tricuspid annuloplasty, especially in lower-to-intermediate risk patients.

It is well known that assessing right heart disease, including hemodynamics, is imprecise if performed only via echocardiographic methods. The echocardiographic guidelines for assessing TR^{3,4} are clear on the methods of measurement, but its severity is often quantified visually, and its visual severity is contingent upon the patient's preload conditions. In addition, indirect measurement of pulmonary artery systolic pressure may be inadequate and may

differ by up to 10% to 20% with the measurement obtained via right heart catheterization.²¹ Nevertheless, several studies^{11,12} with echocardiographic measurements confirm its importance in post-TAVI outcomes and its direct relationship to measurements taken by right catheterization.²² In addition, a dilated tricuspid annulus despite the absence of significant TR could imply a change of therapeutic approach.²³

Implications for Patients With Multivalvular Disease

Tricuspid regurgitation is often related to the grade of PHT^{3,4} and both are related to MR grade; therefore, those patients with MR improvement understandably stand to benefit the most, by achieving a lower rate of PHT and possibly also a subsequently lower TR grade, thus improving survival.¹³ However, up to 16% of the patients included in this cohort demonstrated significant persistent TR despite no or mild baseline MR. Moreover, up to 42% of the patients with moderate baseline mitral valve disease had concomitant significant baseline TR. In this group of patients, making a significant impact on survival will likely require

alternative treatment options to primarily treat either *de novo* right heart disease or disease that could be related to nonreversible changes in the pulmonary vasculature and/or left heart. Whereas the treatment of a dilated tricuspid annulus may be of help in some cases, in others, with severe pulmonary vascular disease, greater attention will be needed for patient selection to avoid TAVI-related futility. Finally, the specific scenario of patients with prior mitral prostheses who undergo TAVI was not explored in this analysis, but in this context, the presence of TR is relatively common, which may play an important role in the prognosis and optimal therapeutic strategy for such patients.^{24,25}

Limitations

The main limitations of the present study include its retrospective design, which may have led to the exclusion of patients deemed surgical or inoperable who did not undergo TAVI. The off-line analysis of the images by operators unaware of the outcomes may have helped to rectify underscoring of the MR grade at the time of baseline evaluation. The follow-up period was limited to the first 6 months after discharge and the assessment of PHT by echocardiography may have been inaccurate as compared with systematic right catheterization. Finally, tricuspid annulus diameter, right chamber dimensions, and right ventricular function were not obtained, which could have shed light on the mechanisms linking TR with poor outcomes.

CONCLUSIONS

The presence of nonsignificant moderate MR did not impact short and mid-term mortality post-TAVI but was associated with a higher rate of rehospitalizations. In patients without significant mitral disease, the presence of moderate or severe TR increased mortality, suggesting that the mechanisms of this problem should be carefully evaluated to determine the best therapeutic strategy and avoid TAVI-related futility.

WHAT IS KNOWN ABOUT THE TOPIC?

- Significant MR clearly impacts in the prognosis of patients undergoing TAVI, but the role of nonsignificant MR and concomitant significant TR remains relatively underexplored.

WHAT DOES THIS STUDY ADD?

- Moderate MR in TAVI recipients influences functional recovery but not mortality whereas, in this scenario, concomitant moderate/severe TR independently predicts in-hospital and mid-term mortality.
- An accurate evaluation of the mechanisms underlying TR may be fundamental to determining the best therapeutic strategy for avoiding TAVI-related futility in TAVI patients with moderate MR.

FUNDING

Project granted by the *Instituto de Salud Carlos III* (PI14/00022), FEDER (*Fondo Europeo de Desarrollo Regional*) funds, *Gerencia Regional de Salud* (SACYL), and Coronary and Structural Course (award to “Multivalvular Score Project”).

CONFLICTS OF INTEREST

I.J. Amat-Santos is advisor for Symetis. L. Nombela-Franco is advisor for St Jude. J.M. Hernández-García is advisor for Medtronic. J. Rodés-Cabau is advisor for Edwards Lifesciences and St Jude.

SUPPLEMENTARY MATERIAL



Supplementary material associated with this article can be found in the online version available at <http://dx.doi.org/10.1016/j.rec.2017.08.019>

REFERENCES

1. Brennan JM, Holmes DR, Sherwood MW, et al. The association of transcatheter aortic valve replacement availability and hospital aortic valve replacement volume and mortality in the United States. *Ann Thorac Surg.* 2014;98:2016–2022.
2. Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: Why are so many denied surgery? *Eur Heart J.* 2005;26:2714–2720.
3. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American college of cardiology/American heart association task force on practice guidelines. *J Am Coll Cardiol.* 2014;63:2438–2488.
4. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2012;33:2451–2496.
5. Kapadia SR, Leon MB, Makkar RR, et al. Articles 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet.* 2015;385:2485–2491.
6. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet.* 2015;385:2477–2484.
7. Barbanti M, Webb JG, Hahn RT, et al. Placement of Aortic Transcatheter Valve Trial Investigators. Impact of preoperative moderate/severe mitral regurgitation on 2-year outcome after transcatheter and surgical aortic valve replacement: insight from the Placement of Aortic Transcatheter Valve (PARTNER) Trial Cohort A. *Circulation.* 2013;128:2776–2784.
8. Cortés C, Amat-Santos IJ, Nombela-Franco L, et al. Mitral Regurgitation After Transcatheter Aortic Valve Replacement: Prognosis, Imaging Predictors, and Potential Management. *JACC Cardiovasc Interv.* 2016;9:1603–1614.
9. Nombela-Franco L, Ribeiro HB, Urena M, et al. Significant mitral regurgitation left untreated at the time of aortic valve replacement: A comprehensive review of a frequent entity in the transcatheter aortic valve replacement era. *J Am Coll Cardiol.* 2014;63:2643–2658.
10. Amat-Santos IJ, Revilla A, López J, et al. Value of CT in patients undergoing self-expandable TAVI to assess outcomes of concomitant mitral regurgitation. *JACC Cardiovasc Imaging.* 2015;8:226–227.
11. O’Sullivan CJ, Wenaweser P, Ceylan O, et al. Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: Insights From the New Proposed Pulmonary Hypertension Classification. *Circ Cardiovasc Interv.* 2015;8:e002358.
12. Schewel D, Schewel J, Martin J, et al. Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hypertension and clinical outcome in patients with severe aortic valvular stenosis. *Clin Res Cardiol.* 2015;104:196.
13. Wilbring M, Tugtekin SM, Ritzmann M, et al. Transcatheter aortic valve implantation reduces grade of concomitant mitral and tricuspid valve regurgitation and pulmonary hypertension. *Eur J Cardiothorac Surg.* 2014;46:818–824.
14. Hutter A, Bleiziffer S, Richter V, et al. Transcatheter aortic valve implantation in patients with concomitant mitral and tricuspid regurgitation. *Ann Thorac Surg.* 2013;95:77–84.
15. Lindman BR, Maniar HS, Jaber WA, et al. Effect of tricuspid regurgitation and the right heart on survival after transcatheter aortic valve replacement: insights from the Placement of Aortic Transcatheter Valves II inoperable cohort. *Circ Cardiovasc Interv.* 2015;8:e002073.
16. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. *J Thorac Cardiovasc Surg.* 2013;145:6–23.
17. Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging.* 2013;14:611–644.
18. Mavromatis K. When Transcatheter Aortic Valve Replacement Is Not Enough: A Step Toward Understanding When Concomitant Mitral Regurgitation Needs Treatment. *JACC Cardiovasc Interv.* 2016;9:1615–1617.

19. Barbanti M, Binder RK, Dvir D, et al. Prevalence and impact of preoperative moderate/severe tricuspid regurgitation on patients undergoing transcatheter aortic valve replacement. *Catheter Cardiovasc Interv.* 2015;85:677–684.
20. Mongrut V, Toubal O, Magne J, et al. Impact of Tricuspid Regurgitation and Tricuspid Annulus Dilation on Mortality After Transcatheter Aortic Valve Replacement. *Circulation.* 2015;132:A18482.
21. D'Alto M, Romeo E, Argiento P, et al. Pulmonary arterial hypertension: the key role of echocardiography. *Echocardiography.* 2015;32:23–37.
22. O'Sullivan CJ, Wenaweser P, Ceylan O, et al. Response To Letter Regarding Article, "Effect of Pulmonary Hypertension Hemodynamic Presentation on Clinical Outcomes in Patients With Severe Symptomatic Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: Insights From the New Proposed Pulmonary Hypertension Classification". *Circ Cardiovasc Interv.* 2015;8:e003064.
23. Van de Veire NR, Braun J, Delgado V, et al. Tricuspid annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgitation in patients with tricuspid annular dilatation undergoing mitral valve repair. *J Thorac Cardiovasc Surg.* 2011;141:1431–1439.
24. Amat-Santos IJ, Cortes C, Castrodeza J, et al. Transcatheter aortic valve implantation in patients with previous mitral prosthesis. *Rev Esp Cardiol.* 2017;70:602–604.
- [25]. Amat-Santos IJ, Cortés C, Nombela Franco L, et al. Prosthetic Mitral Surgical Valve in Transcatheter Aortic Valve Replacement Recipients: A Multicenter Analysis. *JACC Cardiovasc Interv.* 2017;10:1973–1981.